Claims that the Cass Review discarded 101 out of 103 studies of pediatric gender-transition treatment are:
🚨FALSE🚨
Let's examine how Hilary Cass and her team *did* factor in the systematic literature reviews about puberty blockers and cross-sex hormones:
Check out the🧵⬇️
Many of you have seen the tweet threads I've posted since Friday night outlining how the investigators at the University of York conducted their two systematic literature reviews on pediatric gender-transition treatment. I link to those threads in the next two tweets.
One systematic literature review examined puberty-blockers for gender distressed kids. It examined 50 studies, and included in its synthesis one high-quality study and 25 moderate-quality studies.
It did not simply ignore the 24 low-quality studies.
The other systematic lit review examined cross-sex hormone use for gender distress in minors. It examined 53 studies, and included in its synthesis one high-quality study and 33 moderate-quality studies. But it did no simply ignore the 19 low-quality ones.
So what about the Cass Review? How did it make use of the 2 systematic lit reviews?
The claim that Cass simply discarded the 101 moderate/low-quality studies and only looked at the 2 high-quality studies is:
🚨FALSE🚨
She folded the analyses of the 103 studies into her report.
Let's zoom in to the 388-page Cass review. To see where she first folds in the findings of the systematic literature review of cross-sex hormones, go to page 183. Here is how she introduces that paper: cass.independent-review.uk/wp-content/upl…
Cass includes in her report this chart from the lit-review paper on cross-sex hormones, which breaks down all the studies it analyzed and what outcomes they addressed. Cass is pointing out key areas where more research is needed, in particular about fertility outcomes.
On p. 184 of the Cass Review, she goes into considerable detail about the findings of the systematic literature review about cross-sex hormones.
She does not soley focus on the one high-quality study, although she does certainly highlight it.
She refers to all 53 studies.
The Cass review discusses the findings of the systematic literature review on cross-sex hormones for minors amid discussions of lots of other individual papers about pediatric gender-transition treatment.
The Cass Review also folds in the findings from the systematic literature review about puberty blockers for gender distressed minors (p 175). This review examined 50 studies, including one high-quality and 25 moderate-quality studies. cass.independent-review.uk/wp-content/upl…
Cass includes this chart from the review paper on puberty blockers for gender-distressed kids that breaks down the outcomes examined by the 50 studies. It points to areas where much more research is needed, especially about fertility (p 175). cass.independent-review.uk/wp-content/upl…
From page 176 to 177, Cass has lots to say about the specifics of the puberty blocker systematic literature review.
She does not restrict her discussion to the one high-quality study included in the review.
The Cass Review, which runs for 388 pages, includes 15 pages of footnotes of studies, guidelines, and other sources on which the report is based.
Among the X accounts to falsely claim that the Cass Review and 2 of the systematic lit reviews on which it was based simply discarded 101 of 103 studies on pediatric gender-transition treatment:
@DominaMelody, @Marcus_Rasaan, @MammothWhale, @OwenJHurcum.
(There are more...)
Among the X accounts to falsely claim that the Cass Review and 2 of the systematic lit reviews on which it was based simply discarded 101 of 103 studies on pediatric gender-transition treatment:
@JuliaSerano, @Chican3ry, @ErinInTheMorn and @Esqueer_
Debunking podcaster Michael Hobbes also joins in on amplifying the incorrect claim that the Cass Review tossed 101 out of 103 studies on pediatric gender transition treatment. @RottenInDenmark @MammothWhale
Those who say Cass and the lit reviewers simply discarded 101 studies are incorrect. However, because the quality of the study findings was overwhelmingly too weak, they indeed were very limited in which studies they could rely on in assessing safety and efficacy in particular.
English singer @BillyBragg is also among those repeating the incorrect claim that the Cass Review simply discarded over 100 studies on gender-transition treatment for children and only inclined two such studies in the final report.
@billybragg Here is @JuliaSerano’s incorrect tweet, in which she falsely claims that the Cass Review discarded nearly all relevant studies on pediatric gender-transition treatment before crafting its report.
@billybragg @JuliaSerano In this video, British political activist and pundit Owen Jones repeatedly makes the false assertion that the Cass Review excluded any peer-reviewed study about pediatric gender-transition treatment that wasn’t a randomized controlled trial.
Jones also falsely claims that no GIDS patients were sped through the assessment process. In her book, Time to Think, Hannah Barnes documented how many kids were referred for puberty blockers after 3 sessions. Barnes also documented a culture of homophobia some staffers, one that Jones says he cannot imagine could ever happen. But that is what Barnes reported.
@billybragg @JuliaSerano Jones also repeatedly says that the detransition rate is about 1%, saying that long-term studies show this. This despite the fact that Cass said in her report that because of a lack of long-term follow-up, the detransition rate is unknown.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
England’s Health and Human Care Secretary @VictoriaAtkins responds to the Cass Review.
She says part of the NHS “was overtaken by secrecy and ideology that was allowed to trump evidence and safety.”
She vows to stop all puberty blocker prescriptions.
The status of children’s access to puberty blockers in England:
▶️NHS doctors may not prescribe them.
▶️Private clinics technically may, but none are officially sanctioned to and the government seeks to crack down.
▶️The govt also seeks to crack down on overseas prescriptions.
The NHS is supposed to launch a puberty blocker trial. But it needs ethical clearance. At the earliest, it might start early next year. The Cass Review strongly suggested it will only be open to children whose gender dysphoria started in early childhood.
The 1st person to falsely claim that the Cass Review “disregarded nearly all studies” about pediatric gender-transition treatment was apparently activist Alejandra Caraballo. She claimed this 5 hours before the Cass Review was published on April 9, before she’d actually seen it.
Caraballo’s claim about the Cass Review is false, as I demonstrated in this thread. The thread has been added as evidence backing the Community Note placed on English singer @BillyBragg’s false claim about the review, which echoes Caraballo’s.
@billybragg I know Caraballo did not have access to the Cass Review’s final report before the embargo lifted (at 7:01pm ET April 9), because shortly before the embargo was set to lift, she tweeted what she thought was the Cass report. But the link was to the review papers, not the report.
Cass Review fact check, Part II:
The Puberty Blockers Paper
Many have claimed the systematic lit reviews on pediatric gender-transition treatment on which the Cass Review was based took 103 studies, tossed all but 2, and wrote their paper.
**This is false**
Learn more: 🧵⬇️
I previously showed how the systematic literature review on cross-sex hormones for minors actually included 34 high- and moderate-quality studies in its synthesis:
In the puberty blockers systematic lit review, the authors did not, as Erin Reed/Caraballo have claimed, toss all but 2 out of 50 papers before writing their synthesis. They analyzed all 50, and included in their synthesis 1 high-quality study and 25 moderate-quality studies.
There is a claim that only 0.2% of the limited sample of English pediatric gender clinic patients detransitioned. This is false. They have the denominator wrong. Detransitioners by definition have received hormones. 398 kids got hormones. If 8 detransitioned, that’s a 2% rate.
Here is the math:
▶️3,306 GIDS patients included in the analysis
▶️27% were referred to endocrinology: 584 natal females and 307 natal males = 891
▶️81.5% of them got blockers = 726
▶️54.8% of them got hormones = 398
▶️ 8 / 398 = 0.02, or 2%
Keep in mind:
▶️The 3,499 patients audited in this analysis was out of 9,000 total patients at GIDS
▶️Adult gender services refused to share data on the full set
▶️Detransitioning can take ~10 years
▶️There isn't enough follow-up time to fully measure detransitioning among them.
There is a claim circulating that the authors of the systematic literature reviews of puberty blockers and cross-sex hormones for minors took 103 studies, threw out all but 2 for not being high quality, and then wrote their paper.
*This is false.*
To learn more see the 🧵⬇️
Let's look just at the review about cross-sex hormone use for gender dysphoria in minors. This analysis concerned 53 studies (the puberty blocker review looked at 50). No, the authors did not simply disregard all but the single study they deemed high quality. They examined all.
What this paper does is break down what the 53 papers about hormones find and then try to make sense of what all this can tell us. Importantly, it points to key areas where the research is particularly uncertain--pointing to where more research is needed. adc.bmj.com/content/archdi…
Major U.K. Report Finds Pediatric Gender Medicine Is Based on ‘Remarkably Weak Evidence’
Four years in the making, the report has firmly established new, cautious policies on treating youth gender distress in England, I report for @NewYorkSun.
A new era in the care of minors with gender-related distress has begun in England, where a team has published a mammoth report critiquing this branch of pediatrics. Their report characterizes pediatric gender-transition treatment as based on “remarkably weak evidence.”